

Liquid biopsy monitoring program for breast cancer, 7/17

July 2017—Cynvenio Biosystems announced the availability of ClearID Total Insight Breast Cancer, a liquid biopsy monitoring service for patients in treatment and survivors in remission. This comprehensive assessment of a patient's biological health is designed to measure immune health status and detect genetic mutations associated with cancer.

ClearID Total Insight is generally performed at regular intervals throughout the year and consists of four ClearID DNA sequencing tests, four NK-Score immune system assessment tests, and a BRCA 1 & 2 test provided by Cynvenio's partner Color Genomics, according to the company. The Color test identifies 30 of the most common hereditary cancer genes.

[**Cynvenio Biosystems**](#), 805-777-0017